SubcutaneousStimulation of follicular developmentAdult: In combination with follitropin alfa in patient with severe LH and FSH deficiency: 75 units daily until adequate follicular development is achieved. Max: 14 days. Max cycle duration: 5 weeks. Dose may be increased, reduced, or discontinued according to individual response (refer to detailed product guideline). Treatment is followed by HCG to induce ovulation.
|
Primary ovarian failure, uncontrolled thyroid or adrenal dysfunction, active, untreated tumours of the hypothalamus and pituitary gland; ovarian, uterine, or breast cancer, abnormal uterine bleeding, ovarian enlargement or cysts of unknown origin or unrelated to polycystic ovarian disease, sexual organ malformation, fibroid tumours of the uterus. Pregnancy and lactation.
|
Patient with porphyria or a family history of porphyria, polycystic ovarian syndrome, risk factors, recent or on-going thromboembolic disease, history of tubal disease.
|
Significant: Reproductive system neoplasms, ovarian hyperstimulation syndrome, ovarian enlargement, ovarian torsion, thromboembolism, acute porphyria attack, miscarriage, abortion, ectopic pregnancy, multiple births, congenital malformations, thromboembolic events.
Gastrointestinal disorders: Abdominal pain or discomfort, constipation, diarrhoea, flatulence, nausea, vomiting.
General disorders and administration site conditions: Fatigue, malaise, pain, erythema, haematoma, swelling, irritation at the injection site.
Nervous system disorders: Headache.
Reproductive system and breast disorders: Ovarian cyst, ovarian disorder, breast pain, pelvic pain.
|
Evaluate LH and FSH levels prior to initiation of therapy. Monitor follicular maturation with serum oestradiol level and vaginal ultrasound regularly. Monitor signs and symptoms of ovarian hyperstimulation syndrome.
|
Description: Lutropin alfa is a recombinant human luteinising hormone (LH). It binds to and stimulates ovarian theca and granulosa cells, to secrete androgens necessary to produce oestradiol which is needed for follicle stimulating hormone induced-follicular development. Pharmacokinetics: Absorption: Bioavailability: Approx 60%. Time to peak plasma concentration: 9 hours. Distribution: Volume of distribution: 10-14 L. Excretion: Via urine (<5%, as unchanged drug). Elimination half-life: 21 hours.
|
Store below 25°C. Protect from light.
|
|
G03GA07 - lutropin alfa ; Belongs to the class of gonadotropins. Used as ovulation stimulants.
|
Anon. Lutropin Alfa. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 02/05/2018. Anon. Lutropin Alfa. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 02/05/2018. Buckingham R (ed). Lutropin Alfa. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 02/05/2018. Healthcare Logistics. Luveris 75 IU Powder for Injection data sheet 03 January 2013. Medsafe. http://www.medsafe.govt.nz/. Accessed 02/05/2018. Joint Formulary Committee. Lutropin Alfa. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 02/05/2018.
|